Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by youngpupperon Oct 22, 2018 3:38pm

182 Views

Post# 28850567

RE:RE:RE:Advisory Board

bringon10bagger wrote: Antoher step indicative for positive results forthcoming, totally surprising how this trades at peanuts to its future valuation. Big gunners in place for dealing with the big pharma players, hard ball negoitiations on the horizon all equating to BIG BUCKS! IMO mgmt knows a little more than they are willing to share......Slam Dunk!

these releases, letters to shareholders and such IS Antibe sharing whats to come ;)

Bullboard Posts

Calibre discovers significant gold in Newfoundland